BNTX US09075V1026

Report

Real-time Estimate Cboe BZX - 17:18 06/07/2022 BST
157.98	USD		-1.89%

03:40p	Canaccord Genuity Assumes BioNTech at Buy with $192 Price Target	MT
11:17a	MARKETSCREENER'S WORLD PRESS REVIEW : July 6, 2022
11:04a	BIONTECH : Statement on Patent Infringement Lawsuit in Germany - Form 6-K	PU

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

06/29/2022	06/30/2022	07/01/2022	07/05/2022	07/06/2022	Date
141.98(c)	149.1(c)	157.5(c)	161.03(c)	156.87	Last
1 054 370	2 495 583	1 335 180	1 651 658	433 276	Volume
+1.54%	+5.01%	+5.63%	+2.24%	-2.58%	Change

More quotes

Estimated financial data (e)

Sales 2022	16 835 M 17 247 M 14 487 M
Net income 2022	9 580 M 9 814 M 8 244 M
Net cash position 2022	16 333 M 16 733 M 14 055 M
P/E ratio 2022	4,31x
Yield 2022	-

Sales 2023	9 722 M 9 960 M 8 366 M
Net income 2023	4 926 M 5 047 M 4 239 M
Net cash position 2023	25 147 M 25 762 M 21 639 M
P/E ratio 2023	8,49x
Yield 2023	-

Capitalization	38 198 M 39 133 M 32 870 M
EV / Sales 2022	1,30x
EV / Sales 2023	1,34x
Nbr of Employees	3 082
Free-Float	87,3%

More Financials

Company

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer...

Sector

Biotechnology & Medical Research

Calendar

08/08

Earnings Release

More about the company

Ratings of BioNTech SE

Trading Rating :

Investor Rating :

ESG Refinitiv :

B+

More Ratings

All news about BIONTECH SE

03:40p	Canaccord Genuity Assumes BioNTech at Buy with $192 Price Target	MT
11:17a	MARKETSCREENER'S WORLD PRESS REVIEW : July 6, 2022
11:04a	BIONTECH : Statement on Patent Infringement Lawsuit in Germany - Form 6-K	PU
07/05	Germany's CureVac files suit against vaccine rival BioNTech	AQ
07/05	BioNTech Says Will 'Vigorously' Defend Patent Infringement Allegations	MT
07/05	BioNTech Says 'Work is Original' Amid CureVac Lawsuit On mRNA-Related Patents Infringem..	MT
07/05	BIONTECH : Statement on Patent Infringement Lawsuit in Germany	PU
07/05	European ADRs Plunge in Tuesday Trading	MT
07/05	Switzerland to Order 3.5 Million Doses of Pfizer-BioNTech, Moderna COVID-19 Jabs for FY..	MT
07/05	SECTOR UPDATE : Health Care Stocks Decline Premarket Tuesday	MT
07/05	CureVac Sues BioNTech in Germany for Infringement of mRNA-Related Patents	MT
07/05	CureVac Sues BioNTech for Alleged Infringement of Some COVID-19 Vaccine Patents	MT
07/05	CureVac Files Patent Infringement Lawsuit Against BioNTech Over Covid Vaccine	DJ
07/04	African Union Commission Chairperson Statement At the Vaccine Equity for Africa Groundb..	AQ
07/01	European ADRs Fall Sharply in Friday Trading	MT

More news

News in other languages on BIONTECH SE

11:12a	BIONTECH : la pharma attaquée en justice par CureVac
10:49a	BIONTECH, UNILEVER, JPMORGAN EN JUST : Planète Bourse du 6 juillet
08:03a	L'équation se complique à nouveau
07:35a	EN DIRECT DES MARCHES : Schneider, Alstom, EDF, GTT, ASML, BYD, Uniper, Albioma, Holcim...
07/05	MÄRKTE USA/Turbulenter Wochenstart - Ölpreise brechen ein

More news

Analyst Recommendations on BIONTECH SE

03:40p	Canaccord Genuity Assumes BioNTech at Buy with $192 Price Target	MT
07/01	BIONTECH : Deutsche Bank reaffirms its Neutral rating	MD
06/30	BIONTECH : UBS remains Neutral	MD

More recommendations

Provided by Scoopnest.com

Analysis

Zoom Video Communications, Inc.: An attempt to reconnect